168 related articles for article (PubMed ID: 8758902)
1. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.
Joseph IB; Vukanovic J; Isaacs JT
Cancer Res; 1996 Aug; 56(15):3404-8. PubMed ID: 8758902
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
3. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Apr; 55(7):1499-504. PubMed ID: 7533663
[TBL] [Abstract][Full Text] [Related]
4. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic effects of the quinoline-3-carboxamide linomide.
Vukanovic J; Passaniti A; Hirata T; Traystman RJ; Hartley-Asp B; Isaacs JT
Cancer Res; 1993 Apr; 53(8):1833-7. PubMed ID: 7682157
[TBL] [Abstract][Full Text] [Related]
6. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
7. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
Isaacs JT; Pili R; Qian DZ; Dalrymple SL; Garrison JB; Kyprianou N; Björk A; Olsson A; Leanderson T
Prostate; 2006 Dec; 66(16):1768-78. PubMed ID: 16955399
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis.
Joseph IB; Isaacs JT
Prostate; 1996 Sep; 29(3):183-90. PubMed ID: 8827087
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate.
Lucia MS; Anzano MA; Slayter MV; Anver MR; Green DM; Shrader MW; Logsdon DL; Driver CL; Brown CC; Peer CW
Cancer Res; 1995 Dec; 55(23):5621-7. PubMed ID: 7585644
[TBL] [Abstract][Full Text] [Related]
11. Effects of linomide on advanced prostate-seminal vesicle cancers in Lobund-Wistar rats.
Pollard M
Prostate; 1998 Apr; 35(1):43-9. PubMed ID: 9537598
[TBL] [Abstract][Full Text] [Related]
12. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers.
Vukanovic J; Hartley-Asp B; Isaacs JT
Prostate; 1995 May; 26(5):235-46. PubMed ID: 7538663
[TBL] [Abstract][Full Text] [Related]
14. Histogenesis of induced prostate and seminal vesicle carcinoma in Lobund-Wistar rats: a system for histological scoring and grading.
Slayter MV; Anzano MA; Kadomatsu K; Smith JM; Sporn MB
Cancer Res; 1994 Mar; 54(6):1440-5. PubMed ID: 8137245
[TBL] [Abstract][Full Text] [Related]
15. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiogenesis and metastases of the Lewis-lung cell carcinoma by the quinoline-3-carboxamide, Linomide.
Borgström P; Torres Filho IP; Hartley-Asp B
Anticancer Res; 1995; 15(3):719-28. PubMed ID: 7544090
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of Diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 Mice (Dermal Studies) with Dermal Initiation/ Promotion Study of Diethylphthalate and Dimethylphthalate (CAS No. 131-11-3) in Male Swiss (CD-1(R)) Mice.
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1995 May; 429():1-286. PubMed ID: 12616302
[TBL] [Abstract][Full Text] [Related]
18. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
Crawford ED; DeAntoni EP; Ross CA
J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
[TBL] [Abstract][Full Text] [Related]
19. The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice.
Gross DJ; Reibstein I; Weiss L; Slavin S; Stein I; Neeman M; Abramovitch R; Benjamin LE
Clin Cancer Res; 1999 Nov; 5(11):3669-75. PubMed ID: 10589785
[TBL] [Abstract][Full Text] [Related]
20. Effects of thalidomide on DMBA-induced oral carcinogenesis in hamster with respect to angiogenesis.
Yang Y; Ge JP; Zhou ZT
J Oral Pathol Med; 2009 May; 38(5):455-62. PubMed ID: 19141066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
